Biology Reference
In-Depth Information
Clerici M, Balotta C, Meroni L, et al. 1996b. Type 1 cytokine production and low prevalence of
viral isolation correlate with long term non progression in HIV infection. AIDS Res Hum
Retrovir 12: 1053±1061.
Clerici M, Saresella M, Colombo F, et al. 2000a. T lymphocyte maturation abnormalities in unin-
fected newborns and children with vertical exposure to HIV. Blood 96: 3866±3871.
Clerici M, Seminari E, Suter F, et al. 2000b. Di¨erent immunologic pro®les characterize HIV in-
fection in HAART-treated and antiretroviral-naive patients with undetectable viremia. AIDS
14: 109±116.
Cocks BG, Chang CCJ, Carballido JM, et al. 1995. A novel receptor involved in T-cell activation.
Nature 376: 260±264.
Cohen OJ, Kinter A, Fauci AS. 1997. Host factors in the pathogenesis of HIV disease. Immunol Rev
159: 31±48.
Cossarizza A. 1997. T cell repertoire and HIV infection: facts and perspectives. AIDS 11: 1075±
1088.
Dambrosio D, Iellem A, Bonecchi R, et al. 1998. Selective up-regulation of chemokine receptors
CCR4 and CCR8 upon activation of polarized human type 2 TH cells. J Immunol 161: 5111±
5115.
Deaglio S, Morra M, Mallone R, et al. 1998. Human CD38 (ADP-ribosyl cyclase) is a counter-
receptor of CD31, an Ig superfamily member. J Immunol 160: 395±402.
Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, et al. 1994. High expression of APO-1 (CD95)
on T lymphocytes from HIV-infected children. Blood 83: 3101±3110.
de Jong MD, Boucher CA, Danner SA, et al. 1998. Summary of the international consensus sym-
posium on management of HIV, CMV and hepatitis virus infections. Antiviral Res 37: 1±12.
Dolan MJ, Clerici M, Blatt SP, et al. 1995. A T cell functional assay combined with measuremant
of CD4
/CD29
bright
cells in predictive of death in HIV infection. J Infect Dis 172: 79±87.
Farber DL. 2000. T cell memory: heterogeneity and mechanisms. Clin Immunol 95: 173±181.
Ferrero E, Malavasi F. 1997. Human CD38, a leukocyte and ectoenzyme, is a member of a novel
eukaryotic family of nicotinamide adenine dinucleotide -converting enzymes. J Immunol 159:
3858±3865.
Fernandez JE, Deaglio S, Donati D, et al. 1999. Analysis of the distribution of human CD38 and of
its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 12: 81±91.
Finzi D, Silliciano RF. 1998. Viral dynamics in HIV-1 infection. Cell 93: 665±671.
Flexner C. 1998. HIV-protease inhibitors. N Engl J Med 338: 1281±1285.
Garcia S, Fevrier M, Dadaglio G, et al. 1997. Potential deleterious e¨ect of anti-viral cytotoxic
lymphocytes through the CD95 (Fas/APO-1)-mediated pathway during HIV infection. Immunol
Lett 57: 53±58.
Garzino-Demo A, DeVico AL, Gallo RC. 1998. Chemokine receptors and chemokines in HIV. J
Clin Immunol 18: 243±255.
Giorgi JV, Janossy G. 1994. Flow cytometry studies in HIV disease: relevance to AIDS vaccine
development. AIDS 8: S183±S193.
Giorgi JV, Liu Z, Hultin LE, et al. 1993. Elevated levels of CD8
CD38
T cells in HIV infection
add to the prognostic value of low CD4
T cells levels: results of 6 years of follow-up. J Acquir
Immune De®c Syndr 6: 904±912.
Giorgi JV, Ho HN, Hirji K, et al. 1994. CD8
lymphocytes activation at human immunode®ciency
virus type 1 seroconversion: development of HLA-DR
CD38
ÿ
CD8
cells is associated with
subsequent stable CD4
cell levels. J Infect Dis 170: 775±781.
Gougeon ML, Lecoeur H, Boudet F, et al. 1997. Lack of chronic immune activation in HIV-
infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95) induced
apoptosis and preservation of a Th1 phenotype. J Immunol 158: 2964±2976.
